Fusion Antibodies PLC
LSE:FAB
Fusion Antibodies PLC
LSE:FAB
Price:
3.4 GBX
Market Closed
Updated:
May 14, 2024
Fusion Antibodies PLC
Cash Equivalents
|
Fusion Antibodies PLC
Cash Equivalents Peer Comparison
Comparables:
ONT
O
ORPH
DXRX
ERGO
HVO
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Fusion Antibodies PLC
LSE:FAB
|
Cash Equivalents
£487k
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
N/A
|
|
|
Oxford Nanopore Technologies PLC
LSE:ONT
|
Cash Equivalents
£220.5m
|
CAGR 3-Years
40%
|
CAGR 5-Years
44%
|
CAGR 10-Years
N/A
|
|
O
|
Open Orphan PLC
LSE:ORPH
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Diaceutics PLC
LSE:DXRX
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ergomed PLC
LSE:ERGO
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
hVIVO PLC
LSE:HVO
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Fusion Antibodies PLC's Cash Equivalents?
Cash Equivalents
487k
GBP
487k
GBP
Based on the financial report for Sep 30, 2023, Fusion Antibodies PLC's Cash Equivalents amounts to 487k GBP.
What is Fusion Antibodies PLC's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-30%
-30%
Over the last year, the Cash Equivalents growth was -59%. The average annual Cash Equivalents growth rates for Fusion Antibodies PLC have been -47% over the past three years , -30% over the past five years .
You don't have any saved screeners yet
